ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Transmembrane protease serine 2-ETS related gene (TMPRSS2-ERG) gene fusion, the most common genetic alternation in prostate cancer, is associated with protein expression of the oncogene ERG. Recently, an immunohistochemical staining method using an anti-ERG antibody was shown to have a strong correlation with altered ERG protein expression. Methods: We analyzed a total of 303 radical prostatectomy specimens (obtained from Korean prostate cancer cases) using a constructed tissue microarray and ERG immunohistochemical staining. Thereafter, we evaluated the association between ERG expression and clinicopathological factors. Results: The ERG-positive rate was 24.4% (74/303) and significantly higher ERG expression was observed in the subgroup with a lower Gleason score (p=0.004). Analysis of the histologic pattern of prostate adenocarcinomas revealed that tumors with discrete glandular units (Gleason pattern 3) displayed higher frequency of ERG expression (p=0.016). The ERG-positive rate was lower than that found (approximately 50%) in studies involving western populations. Other factors including age, tumor volume, initial protein-specific antigen level, a pathological stage and margin status were not significantly related with the ERG expression. Conclusions: ERG immunohistochemical staining is significantly higher in tumors with well-formed glands and is associated with a lower Gleason score.
Abstract
Background: Transmembrane protease serine 2-ETS related gene (TMPRSS2-ERG) gene fusion, the most common genetic alternation in prostate cancer, is associated with protein expression of the oncogene ERG. Recently, an immunohistochemical staining method using an anti-ERG antibody was shown to have a strong correlation with altered ERG protein expression. Methods: We analyzed a total of 303 radical prostatectomy specimens (obtained from Korean prostate cancer cases) using a constructed tissue microarray and ERG immunohistochemical staining. Thereafter, we evaluated the association between ERG expression and clinicopathological factors. Results: The ERG-positive rate was 24.4% (74/303) and significantly higher ERG expression was observed in the subgroup with a lower Gleason score (p=0.004). Analysis of the histologic pattern of prostate adenocarcinomas revealed that tumors with discrete glandular units (Gleason pattern 3) displayed higher frequency of ERG expression (p=0.016). The ERG-positive rate was lower than that found (approximately 50%) in studies involving western populations. Other factors including age, tumor volume, initial protein-specific antigen level, a pathological stage and margin status were not significantly related with the ERG expression. Conclusions: ERG immunohistochemical staining is significantly higher in tumors with well-formed glands and is associated with a lower Gleason score.
참고문헌 (29)
- Tomlins SA, "Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer", Science, 310, pp.644~648 (2005)
- Demichelis F, "TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort", Oncogene, 26, pp.4596~4599 (2007)
- Rouzier C, "Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data", Cancer Genet Cytogenet, 183, pp.21~27 (2008)
- Chae JY, "TMPRSS2-ERG Gene Fusion and Clinicopathologic Characteristics of Korean Prostate Cancer Patients", UROLOGY, 76 (2010), ELSEVIER SCIENCE INC
- Furusato B, "Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients", Pathol Int, 61, pp.409~414 (2011)
- Miyagi Y, "ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples", Mod Pathol, 23, pp.1492~1498 (2010)
- Attard G, "Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer", Oncogene, 27, pp.253~263 (2008)
- Saramäki OR, "TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis", Clin Cancer Res, 14, pp.3395~3400 (2008)
- Tu JJ, "Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues", Mod Pathol, 20, pp.921~928 (2007)
- Park K, "Antibody-based detection of ERG rearrangement-positive prostate cancer", Neoplasia, 12, pp.590~598 (2010)
- Chaux A, "Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas", Am J Surg Pathol, 35, pp.1014~1020 (2011)
- van Leenders GJ, "Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice", Mod Pathol, 24, pp.1128~1138 (2011)
- Falzarano SM, "ERG gene rearrangement status in prostate cancer detected by immunohistochemistry", Virchows Arch, 459, pp.441~447 (2011)
- Epstein JI, "The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma", Am J Surg Pathol, 29, pp.1228~1242 (2005)
- Kim J, "Interrogating genomic and epigenomic data to understand prostate cancer", Biochim Biophys Acta, 1825, pp.186~196 (2012)
- Iwamoto M, "The role of ERG (ets related gene) in cartilage development", Osteoarthritis Cartilage, 9(Suppl A), pp.41~47 (2001)
- Narod SA, "Fusion in the ETS gene family and prostate cancer", Br J Cancer, 99, pp.847~851 (2008)
- Barwick BG, "Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts", Br J Cancer, 102, pp.570~576 (2010)
- Hermans KG, "Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer", Clin Cancer Res, 15, pp.6398~6403 (2009)
- Yoshimoto M, "Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome", Mod Pathol, 21, pp.1451~1460 (2008)
- Nam RK, "Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression", Cancer Biol Ther, 6, pp.40~45 (2007)
- Minner S, "ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy", Clin Cancer Res, 17, pp.5878~5888 (2011)
- Mehra R, "Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer", Mod Pathol, 20, pp.538~544 (2007)
- Mosquera JM, "Morphological features of TMPRSS2-ERG gene fusion prostate cancer", J Pathol, 212, pp.91~101 (2007)
- Perner S, "TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer", Cancer Res, 66, pp.8337~8341 (2006)
- Bismar TA, "ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality", Eur J Cancer, 48, pp.538~546 (2012)
- Darnel AD, "TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort", Cancer Biol Ther, 8, pp.125~130 (2009)
- Hoogland AM, "ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer", Mod Pathol, 25, pp.471~479 (2012)
- Gopalan A, "TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy", Cancer Res, 69, pp.1400~1406 (2009)